StockNews.com started coverage on shares of Ocular Therapeutix (NASDAQ:OCUL – Get Rating) in a report released on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock.
OCUL has been the subject of several other research reports. HC Wainwright restated a buy rating and issued a $11.00 price target on shares of Ocular Therapeutix in a report on Tuesday, March 7th. JMP Securities dropped their target price on Ocular Therapeutix from $12.00 to $11.00 and set a market outperform rating on the stock in a research report on Tuesday, March 7th.
Ocular Therapeutix Stock Performance
OCUL opened at $4.96 on Thursday. The company has a debt-to-equity ratio of 1.53, a current ratio of 4.13 and a quick ratio of 4.07. The business’s fifty day simple moving average is $4.82 and its 200-day simple moving average is $4.18. Ocular Therapeutix has a 12-month low of $2.57 and a 12-month high of $6.53.
Insider Buying and Selling
Hedge Funds Weigh In On Ocular Therapeutix
Several hedge funds and other institutional investors have recently bought and sold shares of OCUL. Federated Hermes Inc. purchased a new stake in shares of Ocular Therapeutix in the 1st quarter valued at $3,080,000. Marshall Wace LLP purchased a new stake in Ocular Therapeutix in the third quarter valued at $2,207,000. Renaissance Technologies LLC grew its position in Ocular Therapeutix by 537.7% during the 1st quarter. Renaissance Technologies LLC now owns 510,805 shares of the biopharmaceutical company’s stock worth $2,528,000 after purchasing an additional 430,705 shares during the period. Barclays PLC grew its position in Ocular Therapeutix by 9,659.2% during the 4th quarter. Barclays PLC now owns 318,834 shares of the biopharmaceutical company’s stock worth $896,000 after purchasing an additional 315,567 shares during the period. Finally, UBS Group AG raised its stake in shares of Ocular Therapeutix by 881.0% during the 2nd quarter. UBS Group AG now owns 342,228 shares of the biopharmaceutical company’s stock valued at $1,376,000 after buying an additional 307,344 shares during the last quarter. Institutional investors and hedge funds own 55.40% of the company’s stock.
About Ocular Therapeutix
Ocular Therapeutix, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
- Get a free copy of the StockNews.com research report on Ocular Therapeutix (OCUL)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.